Search Results

Applied StemCell, Inc. is pleased to announce the addition of two accomplished professionals to its C-level executive team: George Hong (Chief Commercial Officer) and Timothy J. Largen (Chief Operating Officer).

QHP Capital, announced its acquisition of Applied StemCell, Inc., a leading cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry in developing and manufacturing cell and gene products.

STEMCELL Technologies is pleased to announce the acquisition of Propagenix Inc.

Applied StemCell, Inc. and the California Institute for Regenerative Medicine have partnered as Industry Resource Partners.

Applied UV, Inc. (NASDAQ: AUVI) (the “Company”), a leader in smart building technology solutions, today announced the closing of its previously announced registered direct offering and concurrent private placement with institutional investors.

Applied DNA Sciences, Inc. announced that its molecular diagnostics subsidiary, Applied DNA Clinical Labs, LLC, will utilize the GenXys Health Care Systems suite of clinical decision support software for interpretation and reporting of ADCL’s New York State Department of Health-approved TR8™ pharmacogenomic test.

STEMCELL Technologies is pleased to announce the acquisition of substantially all assets of SQZ Biotechnologies Company —a Massachusetts-based biotech known for its game-changing method of introducing a variety of therapeutic cargo into cells by squeezing them rather than using electricity.

Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. announced the closing of its previously announced transaction pursuant to which AMT will merge with Cyclo Therapeutics in an all-stock transaction.

Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, announced the pricing of a public offering with gross proceeds to the Company expected to be approximately $12.0 million, before deducting placement agent fees and other estimated expenses payable by the Company.

Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that on May 9, 2024, it received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market informing the Company that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).